Cargando…

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo

Hypoxia is an important selective force in the clonal evolution of tumours. Through HIF-1 and other transcription factors combined with tumour-specific genetic alterations, hypoxia is a dominant factor in the angiogenic phenotype. Cellular adaptation to hypoxia is an important requirement of tumour...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, K, Gietema, J A, Shida, S, Selvakumaran, M, Fonrose, X, Haas, N B, Testa, J, O'Dwyer, P J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361533/
https://www.ncbi.nlm.nih.gov/pubmed/16333244
http://dx.doi.org/10.1038/sj.bjc.6602864
_version_ 1782153234709741568
author Yao, K
Gietema, J A
Shida, S
Selvakumaran, M
Fonrose, X
Haas, N B
Testa, J
O'Dwyer, P J
author_facet Yao, K
Gietema, J A
Shida, S
Selvakumaran, M
Fonrose, X
Haas, N B
Testa, J
O'Dwyer, P J
author_sort Yao, K
collection PubMed
description Hypoxia is an important selective force in the clonal evolution of tumours. Through HIF-1 and other transcription factors combined with tumour-specific genetic alterations, hypoxia is a dominant factor in the angiogenic phenotype. Cellular adaptation to hypoxia is an important requirement of tumour progression independent of angiogenesis. The adaptive changes, insofar as they alter hypoxia-induced apoptosis, are likely to determine responsiveness to antiangiogenic strategies. To investigate this adaptation of tumour cells to hypoxia, we recreated in vitro the in vivo situation of chronic intermittent exposure to low-oxygen levels. The colon carcinoma cell lines HT29 and HCT116 were subjected to 40 episodes of sublethal hypoxia (4 h) three times a week. The resulting two hypoxia-conditioned cell lines have been maintained in culture for more than 2 years. In both cell lines changes in doubling times occurred: in HT29 an increase, and in HCT116 a decrease. Cell survival in response to hypoxia and to DNA damage differed strikingly in the two cell lines. The HT29 hypoxia-conditioned cells were more resistant than the parental line to a 24 h hypoxic challenge, while those from HCT116 surprisingly were more sensitive. Sensitivity to cisplatin in vitro was also significantly different for the hypoxia-conditioned compared with the parental lines, suggesting a change in pathways leading to apoptosis following DNA damage signaling. The growth of both conditioned cell lines in vivo as xenografts in immunodeficient (SCID) mice was more rapid than their parental lines, and was accompanied in each by evidence of enhanced vascular proliferation as a consequence of the hypoxia-conditioning. Thus the changes in apoptotic susceptibility were independent of altered angiogenesis. The derivation of these lines provides a model for events within hypoxic regions of colon cancers, and for the acquisition of resistance and sensitivity characteristics that may have therapeutic implications for the use of antiangiogenesis drugs.
format Text
id pubmed-2361533
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23615332009-09-10 In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo Yao, K Gietema, J A Shida, S Selvakumaran, M Fonrose, X Haas, N B Testa, J O'Dwyer, P J Br J Cancer Translational Therapeutics Hypoxia is an important selective force in the clonal evolution of tumours. Through HIF-1 and other transcription factors combined with tumour-specific genetic alterations, hypoxia is a dominant factor in the angiogenic phenotype. Cellular adaptation to hypoxia is an important requirement of tumour progression independent of angiogenesis. The adaptive changes, insofar as they alter hypoxia-induced apoptosis, are likely to determine responsiveness to antiangiogenic strategies. To investigate this adaptation of tumour cells to hypoxia, we recreated in vitro the in vivo situation of chronic intermittent exposure to low-oxygen levels. The colon carcinoma cell lines HT29 and HCT116 were subjected to 40 episodes of sublethal hypoxia (4 h) three times a week. The resulting two hypoxia-conditioned cell lines have been maintained in culture for more than 2 years. In both cell lines changes in doubling times occurred: in HT29 an increase, and in HCT116 a decrease. Cell survival in response to hypoxia and to DNA damage differed strikingly in the two cell lines. The HT29 hypoxia-conditioned cells were more resistant than the parental line to a 24 h hypoxic challenge, while those from HCT116 surprisingly were more sensitive. Sensitivity to cisplatin in vitro was also significantly different for the hypoxia-conditioned compared with the parental lines, suggesting a change in pathways leading to apoptosis following DNA damage signaling. The growth of both conditioned cell lines in vivo as xenografts in immunodeficient (SCID) mice was more rapid than their parental lines, and was accompanied in each by evidence of enhanced vascular proliferation as a consequence of the hypoxia-conditioning. Thus the changes in apoptotic susceptibility were independent of altered angiogenesis. The derivation of these lines provides a model for events within hypoxic regions of colon cancers, and for the acquisition of resistance and sensitivity characteristics that may have therapeutic implications for the use of antiangiogenesis drugs. Nature Publishing Group 2005-12-12 2005-12-06 /pmc/articles/PMC2361533/ /pubmed/16333244 http://dx.doi.org/10.1038/sj.bjc.6602864 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Yao, K
Gietema, J A
Shida, S
Selvakumaran, M
Fonrose, X
Haas, N B
Testa, J
O'Dwyer, P J
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
title In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
title_full In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
title_fullStr In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
title_full_unstemmed In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
title_short In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
title_sort in vitro hypoxia-conditioned colon cancer cell lines derived from hct116 and ht29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361533/
https://www.ncbi.nlm.nih.gov/pubmed/16333244
http://dx.doi.org/10.1038/sj.bjc.6602864
work_keys_str_mv AT yaok invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo
AT gietemaja invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo
AT shidas invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo
AT selvakumaranm invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo
AT fonrosex invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo
AT haasnb invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo
AT testaj invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo
AT odwyerpj invitrohypoxiaconditionedcoloncancercelllinesderivedfromhct116andht29exhibitalteredapoptosissusceptibilityandamoreangiogenicprofileinvivo